A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047).
Michelle MonjeTabitha CooneyJohn W GlodJie HuangCody J PeerDamien FauryPatricia BaxterKim KramerAlicia LenzenNathan J RobisonLindsay KilburnAnna VinitskyWilliam D FiggNada JabadoMaryam FouladiJason R FangusaroArzu Onar-ThomasIra J DunkelKatherine E WarrenPublished in: Neuro-oncology (2023)
The MTD of panobinostat is 10 mg/m 2/dose administered 3 times per week for 3 weeks on/1 week off in children with progressive DIPG/DMG and 22 mg/m 2/dose administered 3 times per week for 1 week on/1 week off when administered in a similar population pre-progression. The most common toxicity for both schedules was myelosuppression.